Myriad Genetics And SOPHiA GENETICS Collaborate To Develop And Provide Pharmaceutical Companies With Innovative Global Liquid Biopsy Companion Diagnostic Test

Author: Benzinga Newsdesk | September 23, 2025 07:02am

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS' broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.

Posted In: MYGN SOPH